Memorial Sloan Kettering Cancer Center

St. Jude Children's Research Hospital

University of Kentucky Research Foundation

Sloan-kettering Institute for Cancer Research

Virttu Biologics Limited

Crusade Laboratories Limited

Bhuvanesh Singh

Daniel C Scott

Jared T Hammill

Jaeki Min

R Kiplin Guy

Brenda A Schulman

Deepak Bhasin

Susanne Moira Brown

Rodney Kiplin Guy

Paul Dunn

Ian Ganly

Pabbathi Thirumal Reddy, Legal Representative

Hoshin Kim

Brenda Arlene Schulman

A DCN1/2-mediated cullin neddylation modulator; a method for treating disorders associated with dysfunctional DCN1 and/or UBC12, Alzheimer's disease, other neurodegenerative diseases, bacterial infections, or viral infections; and a method for treating cancers are provided. The DCN1/2-mediated cullin neddylation modulator includes a compound according to Formula I disclosed herein. The methods include administering to a mammal a therapeutically effective amount of a compound according to Formula I. Also provided herein is a pharmaceutical composition including a therapeutically effective amount of a compound according to Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Pharmaceutically active pyrazolo-pyridone modulators of DCN1/2-mediated cullin neddylation

In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Methods and compositions of inhibiting DCN1-UBC12 interaction

An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.

Methods for treating cancer using herpes simplex virus expressing antisense to the squamous cell carcinoma related oncogene

Novel nucleic acids and polypeptides encoded thereby are provided that are highly duplicated and overexpressed in squamous cell carcinomas of a variety of tissues. Antibodies specific for binding the novel polypeptides are also provided. The invention further discloses several assays for gene duplication and overexpression of the novel gene and excessive production of the novel polypeptide in a sample. These assays permit assessing copy number in a sample from a subject, and contribute to the diagnosis, prognosis and development of therapeutic strategy for a pathology such as squamous cell carcinoma in a subject.

Carcinoma-related genes and polypeptides and methods of use thereof

Growing community of inventors

Old Westbury, NY, United States of America

Bhuvanesh Singh